Patients with advanced hepatocellular carcinoma (HCC) receiving atezolizumab-bevacizumab treatment were more likely to experience variceal bleeding if they had a low platelet count, main portal ...

Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy ...

Approved by the US Food and Drug Administration for HCC, the combination of atezolizumab and bevacizumab received the ...